Targeting Targeted Therapies

• Druker BJ : Translation of the Philadelphia chromosome into therapy for CML.Blood112(13) , 4808–4817 (2008).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A , CortesJ: Molecular biology of BCR-ABL1-positive chronic myeloid leukemia.Blood113(8) , 1619–1630 (2009).
   PubMed Web of Science ®Google Scholar
• Sims AH , HowellA, HowellSJ, ClarkeRB: Origins of breast cancer subtypes and therapeutic implications.Nat. Clin. Pract. Oncol.4(9) , 516–525 (2007).
   PubMedGoogle Scholar
• Slamon DJ , Leyland-JonesB, ShakS et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N. Engl. J. Med.344(11) , 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Chung KY , ShiaJ, KemenyNE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.J. Clin. Oncol.23(9) , 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Allegra CJ , JessupJM, SomerfieldMR et al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.J. Clin. Oncol.27(12) , 2091–2096 (2009).
   PubMed Web of Science ®Google Scholar
• Higano CS , SmallEJ, SchellhammerP et al.: Sipuleucel-T.Nat. Rev. Drug Discov.9(7) , 513–514 (2010).
   PubMed Web of Science ®Google Scholar
• Louahed J , DrenoB, GaulisS et al.: Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment.Ann. Oncol.19(Suppl. 8) , VIII61–VIII62 (2008).
   Web of Science ®Google Scholar
• Jassem J , VansteenkisteJ, ZielinskiM et al.: Gene expression signature is a potential predictive factor for efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage Ib/II nonsmall cell lung cancer (NSCLC).Ann. Oncol.19(Suppl. 8) , VIII61–VIII62 (2008).
   Web of Science ®Google Scholar
• Peeters O : Use of antigen-specific cancer immunotherapeutics (ASCIs) in the treatment of NSCLC. Presented at: Targeted Cancer Therapies – Translating Innovative Cancer Research into Effective Targeted Therapies. London, UK, 25–27 May 2010.
   Google Scholar
• Acres B , Berangere M-B, Grellier B et al.: A signature of circulating biomarkers correlates with clinical outcome in a randomized Phase IIb trial evaluating the therapeutic vaccine TG4010 in NSCLC patients. Presented at: AACR Annual Meeting. Denver, CO, USA, 18–22 April 2009.
   Google Scholar
• Amato RJ , DruryN, NaylorS et al.: Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a Phase II trial.J. Immunother.31(6) , 577–585 (2008).
   PubMed Web of Science ®Google Scholar
• Amato RJ , ShinglerW, GoonewardenaM et al.: Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-α (IFN-α): a Phase II trial.J. Immunother.32(7) , 765–772 (2009).
   PubMed Web of Science ®Google Scholar
• Amato RJ , ShinglerW, NaylorS et al.: Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a Phase II trial.Clin. Cancer Res.14(22) , 7504–7510 (2008).
   PubMed Web of Science ®Google Scholar
• Elkord E , DangoorA, BurtDJ et al.: Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).Cancer Immunol. Immunother.58(10) , 1657–1667 (2009).
   PubMed Web of Science ®Google Scholar
• Harrop R , ConnollyN, RedchenkoI et al.: Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial.Clin. Cancer Res.12(11 Pt 1) , 3416–3424 (2006).
   PubMed Web of Science ®Google Scholar
• Harrop R , DruryN, ShinglerW et al.: Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.Cancer Immunol. Immunother.57(7) , 977–986 (2007).
   Web of Science ®Google Scholar
• Harrop R , DruryN, ShinglerW et al.: Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.Clin. Cancer Res.13(15 Pt 1) , 4487–4494 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkins RE , MacdermottC, ShablakA et al.: Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-α.J. Immunother.32(4) , 424–429 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufman H , TabackB, ShermanW et al.: Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.J. Transl. Med.7(1) , 2 (2009).
   PubMedGoogle Scholar
• Hawkins R , HarropR, NaylorS et al.: TRIST: a randomised, double blind, placebo controlled Phase III study of MVA-5T4 in metastatic renal cancer patients.Eur. J. Cancer Suppl.7(3) , 11 (2009).
   Google Scholar

▪ Websites

• NCCN: NCCN Updates Guidelines for Colorectal Cancer www.nccn.org/about/news/newsinfo.asp?NewsID=194 (Accessed 6July2010)
   Google Scholar
• Abbott press release: Abbott to Collaborate with GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0827.htm (Accessed 7July2010)
   Google Scholar